InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement
November 11, 2021

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently announced a collaboration with researchers at the University of Wisconsin-Madison as part of preparations toward planned phase 2b studies. Under the partnership, Dr. Paul Hutson, PharmD, and Dr. Christopher Nicholas, Ph.D., will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803. The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803. “This partnership is the latest in a series of collaborations with scholars, institutions and companies,” reads a recent article. “In July, Tryp announced an agreement with the University of Michigan as part of upcoming bridging studies designed to grow its portfolio for TRP-8803 and facilitate the drug formulation’s advancement into phase 2b trials. In August, Tryp announced partnerships with Calvert Labs — an Altasciences company — and Gad Consulting Services. Under the terms of the agreement, Calvert Labs will design and execute exploratory bridging studies to generate toxicology and blood exposure level data for TRP-8803. Tryp will then work with Altasciences to perform clinical pharmacology studies in healthy volunteer patients.”

To view the full article, visit https://ibn.fm/Gr5e9

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment chronic pain and other indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).